Form 4: Integra LifeSciences Holdings Corp: Executive Robert T. Davis Jr. Reports Stock Transactions

EVP & President, TT, Robert T. Davis Jr. of Integra LifeSciences Holdings Corp reports acquisition and disposal of common stock and stock options.

Summary

• On March 11 and 12, 2024, Robert T. Davis Jr., EVP & President, TT of Integra LifeSciences Holdings Corp, reported transactions involving the company's common stock and non-qualified stock options.
• Davis disposed of 458 shares of common stock at $36.22 on March 11, 2024, and another 1,952 shares at the same price.
• He also acquired 6,478 and 13,805 shares of common stock on March 11, 2024, at $0.
• On March 12, 2024, Davis disposed of 443 shares at $35.88 and another 1,581 shares at the same price.
• Davis also acquired 14,963 non-qualified stock options with an exercise price of $36.22, exercisable starting March 11, 2024, and expiring on March 11, 2032.
• Following these transactions, Davis beneficially owns 65,107 shares of common stock and 14,963 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Positives

• The acquisition of 20,283 shares of common stock at $0 suggests the granting of stock as compensation.
• The acquisition of 14,963 non-qualified stock options indicates an incentive for future performance.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company executive, providing transparency to investors about insider activity. It's common for executives to receive stock options and restricted stock as part of their compensation packages, and their transactions are closely watched by the market.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units (RSUs) to align management's interests with those of shareholders.
• The vesting schedule of 25% per year is a standard practice for stock options.
• Comparing Davis's stock ownership and transactions to those of executives at similar-sized medical technology companies (e.g., NuVasive, Globus Medical) could provide insights into industry norms.

Stakeholder Impact

• Shareholders may be interested in these transactions as they provide insight into executive sentiment and potential future actions.
• The transactions themselves are unlikely to have a significant impact on other stakeholders.

Key Dates